Epidermic toxic necrolysis induced by co-trimoxazole

Authors

  • Rolando Rodríguez Hernández Hospital General Docente “Orlando Pantoja Tamayo”, Universidad de Ciencias Médicas, Contramaestre, Santiago de Cuba
  • Mercedes Rodríguez del Toro Hospital General Docente “Orlando Pantoja Tamayo”, Universidad de Ciencias Médicas, Contramaestre, Santiago de Cuba
  • Carlos Pantoja Prosper Policlínico Docente América I, Universidad de Ciencias Médicas, Contramaestre, Santiago de Cuba

Keywords:

epidermic toxic necrolysis, Lyell syndrome, co-trimoxazole, self-medication.

Abstract

The case report of a 60 years patient with a history of hypertension, reason why she had treatment with nifedipine, who went to the Emergency Room of "Orlando Pantoja Tamayo" Teaching General Hospital in Contramaestre, Santiago de Cuba, due to diarrheical stools, vomits, hyperthermia (38 0C) and generalized skin injuries in the type of erythemato-scabby pustules with flictenas and pain is described.  The patient referred that she was accustomed to self-medication with co-trimoxazole due to repeated urinary infections and that she was consuming this medication for 3 days.  The pathological study showed an epidermic toxic necrolysis (Lyell syndrome).  In spite of the medical cares, she had an unfavorable clinical course and she complicated with an acute renal failure, leading to death.

Downloads

Download data is not yet available.

Author Biography

Rolando Rodríguez Hernández, Hospital General Docente “Orlando Pantoja Tamayo”, Universidad de Ciencias Médicas, Contramaestre, Santiago de Cuba

Departamento de farmacia Jefe del departamento

References

1. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergol Int. 2010; 59(4): 325-32.

2. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2013; 115(2): 149-53.

3. Del Pozzo-Magana BR, Lazo-Langer A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of the treatment of drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011; 18(1): 121-33.

4. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008; 128(1): 35-44.

5. Wanat KA, Anadakat MJ, Alekotta PA. Seasonal variations of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis associated with: Trimethoprim-Sulfamethoxazole. J Am Acad Dermatol. 2009; 60(4): 589-94.

6. Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser L, Jameson J, et al. Cutaneous drug reactions. En: Harrison’s principles of internal medicine. 17 ed. New York: McGraw-Hill Professional; 2008.

7. Reynoso von Drateln C, Villagrán Plascencia M, Rodríguez Martínez N, Rodríguez Beltrán S, Acosta Ramírez CA. Abordaje terapéutico del síndrome de necrólisis epidérmica tóxica (síndrome de Brocq-Lyell). Dermatología Rev Mex. 2009; 53(6): 288-94.

8. Harr T, French LE. Severe cutaneous adverse reactions: acute generalized exanthematous pustulosis, toxic epidermal necrolysis and Stevens-Johnson syndrome. Med Clin North Am. 2010; 94(4): 727-42.

9. Worswick S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review treatment options. Dermatol Ther. 2011; 24(2): 207-18.

Downloads

Published

2016-11-07

How to Cite

1.
Rodríguez Hernández R, Rodríguez del Toro M, Pantoja Prosper C. Epidermic toxic necrolysis induced by co-trimoxazole. MEDISAN [Internet]. 2016 Nov. 7 [cited 2025 Jun. 3];20(11). Available from: https://medisan.sld.cu/index.php/san/article/view/488

Issue

Vol. 20 No. 11 (2016): MEDISAN

Section

Case Reports

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.